Breaking News

3M to Manufacture Mylan’s Sirdupla

First biosimilar to GlaxoSmithKline’s Seretide Evohaler

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Mylan has launched the first biosimilar to GlaxoSmithKline’s Seretide Evohaler (salmeterol xinafoate/fluticasone propionate) under the name Sirdupla in the UK. Sirdupla is a pressurized metered-dose inhaler (pMDI) indicated to treat symptoms of asthma. 3M Drug Delivery Systems will manufacture the product, which is available in 125/25 mcg and 250/25 mcg with 120 doses. Mylan President Rajiv Malik said, “Mylan is excited to be the first company to offer adult asthma patients in the UK the gene...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters